{"parse":{"title":"Phases of clinical research","pageid":34382035,"revid":857380715,"text":{"*":"<div class=\"mw-parser-output\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">Clinical trial</a></div>\n<p>The <b>phases of clinical research</b> are the steps in which scientists do experiments with a <a href=\"/wiki/Health_intervention\" class=\"mw-redirect\" title=\"Health intervention\">health intervention</a> in an attempt to find enough evidence for a process which would be useful as a <a href=\"/wiki/Medical_treatment\" class=\"mw-redirect\" title=\"Medical treatment\">medical treatment</a>. In the case of pharmaceutical study, the phases start with <a href=\"/wiki/Drug_design\" title=\"Drug design\">drug design</a> and <a href=\"/wiki/Drug_discovery\" title=\"Drug discovery\">drug discovery</a> then proceed on to <a href=\"/wiki/Animal_testing\" title=\"Animal testing\">animal testing</a>. If this is successful, they begin the clinical phase of development by testing for safety in a few <a href=\"/wiki/Human_subject_research\" title=\"Human subject research\">human subjects</a> and expand to test in many study participants to determine if the treatment is effective.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Summary\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Summary</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Pre-clinical_studies\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Pre-clinical studies</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Phase_0\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Phase 0</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Phase_I\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Phase I</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Phase_II\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Phase II</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Success_rate\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">Success rate</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Phase_III\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Phase III</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Success_rate_2\"><span class=\"tocnumber\">6.1</span> <span class=\"toctext\">Success rate</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#Phase_IV\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Phase IV</span></a></li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Overall_cost\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Overall cost</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#References\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Summary\">Summary</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=1\" title=\"Edit section: Summary\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Clinical trials involving new drugs are commonly classified into four phases. Individual trials may encompass more than one phase. A common example of this is combined phase I/II or phase II/III trials. Therefore, it may be easier to think of early phase studies and late phase studies.<sup id=\"cite_ref-DeMets_1-0\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>  The drug-development process will normally proceed through all four phases over many years. If the drug successfully passes through Phases I, II, and III, it will usually be approved by the national regulatory authority for use in the general population. Phase IV are 'post-approval' studies.\n</p>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<th colspan=\"7\" style=\"background-color: #CCEEEE;\">Summary of clinical trial phases\n</th></tr>\n<tr>\n<th>Phase\n</th>\n<th>Primary goal\n</th>\n<th>Dose\n</th>\n<th>Patient monitor\n</th>\n<th>Typical number of participants\n</th>\n<th>Success rate<sup id=\"cite_ref-fda_2-0\" class=\"reference\"><a href=\"#cite_note-fda-2\">&#91;2&#93;</a></sup>\n</th>\n<th>Notes\n</th></tr>\n<tr>\n<td>Preclinical\n</td>\n<td>Testing of drug in non-human subjects, to gather <a href=\"/wiki/Efficacy\" title=\"Efficacy\">efficacy</a>, <a href=\"/wiki/Toxicity\" title=\"Toxicity\">toxicity</a> and <a href=\"/wiki/Pharmacokinetic\" class=\"mw-redirect\" title=\"Pharmacokinetic\">pharmacokinetic</a> information\n</td>\n<td>unrestricted\n</td>\n<td>scientific researcher\n</td>\n<td>not applicable (<i><a href=\"/wiki/In_vitro\" title=\"In vitro\">in vitro</a></i> and <i><a href=\"/wiki/In_vivo\" title=\"In vivo\">in vivo</a></i> only)\n</td>\n<td>\n</td>\n<td>\n</td></tr>\n<tr>\n<td>Phase 0\n</td>\n<td><a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">Pharmacokinetics</a>; particularly, oral bioavailability and half-life of the drug\n</td>\n<td>very small, subtherapeutic\n</td>\n<td>clinical researcher\n</td>\n<td>10 people\n</td>\n<td>\n</td>\n<td>often skipped for phase I\n</td></tr>\n<tr>\n<td>Phase I\n</td>\n<td>Testing of drug on healthy volunteers for safety; involves testing multiple doses (<a href=\"/wiki/Dose-ranging\" class=\"mw-redirect\" title=\"Dose-ranging\">dose-ranging</a>)\n</td>\n<td>often subtherapeutic, but with ascending doses\n</td>\n<td>clinical researcher\n</td>\n<td>20\u2013100 normal healthy volunteers (or for cancer drugs, cancer patients)\n</td>\n<td>approximately 70%\n</td>\n<td>determines whether drug is safe to check for efficacy\n</td></tr>\n<tr>\n<td>Phase II\n</td>\n<td>Testing of drug on patients to assess efficacy and side effects\n</td>\n<td>therapeutic dose\n</td>\n<td>clinical researcher\n</td>\n<td>100\u2013300 patients with specific diseases\n</td>\n<td>approximately 33%\n</td>\n<td>determines whether drug can have any efficacy; at this point, the drug is not presumed to have any therapeutic effect whatsoever\n</td></tr>\n<tr>\n<td>Phase III\n</td>\n<td>Testing of drug on patients to assess efficacy, effectiveness and safety\n</td>\n<td>therapeutic dose\n</td>\n<td>clinical researcher and personal physician\n</td>\n<td>300\u20133,000 patients with specific diseases\n</td>\n<td>25\u201330%\n</td>\n<td>determines a drug's therapeutic effect; at this point, the drug is presumed to have some effect\n</td></tr>\n<tr>\n<td>Phase IV\n</td>\n<td><a href=\"/wiki/Postmarketing_surveillance\" title=\"Postmarketing surveillance\">Postmarketing surveillance</a> \u2013 watching drug use in public\n</td>\n<td>therapeutic dose\n</td>\n<td>personal physician\n</td>\n<td>anyone seeking treatment from their physician\n</td>\n<td>N/A\n</td>\n<td>watch drug's long-term effects\n</td></tr>\n</tbody></table>\n<h2><span class=\"mw-headline\" id=\"Pre-clinical_studies\">Pre-clinical studies</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=2\" title=\"Edit section: Pre-clinical studies\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Before pharmaceutical companies start clinical trials on a drug, they conduct extensive <a href=\"/wiki/Pre-clinical_development\" title=\"Pre-clinical development\">pre-clinical studies</a>. These involve <a href=\"/wiki/In_vitro\" title=\"In vitro\">in vitro</a> (test tube or cell culture) and <a href=\"/wiki/In_vivo\" title=\"In vivo\">in vivo</a> (animal) experiments using wide-ranging doses of the study drug to obtain preliminary <a href=\"/wiki/Efficacy\" title=\"Efficacy\">efficacy</a>, <a href=\"/wiki/Toxicity\" title=\"Toxicity\">toxicity</a> and <a href=\"/wiki/Pharmacokinetic\" class=\"mw-redirect\" title=\"Pharmacokinetic\">pharmacokinetic</a> information. Such tests assist pharmaceutical companies to decide whether a drug candidate has scientific merit for further development as an <a href=\"/wiki/Investigational_new_drug\" class=\"mw-redirect\" title=\"Investigational new drug\">investigational new drug</a>.\n</p>\n<h2><span class=\"mw-headline\" id=\"Phase_0\">Phase 0</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=3\" title=\"Edit section: Phase 0\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Phase 0 is a recent designation for optional exploratory trials conducted in accordance with the United States <a href=\"/wiki/Food_and_Drug_Administration_(United_States)\" class=\"mw-redirect\" title=\"Food and Drug Administration (United States)\">Food and Drug Administration's</a> (FDA) 2006 Guidance on Exploratory <a href=\"/wiki/Investigational_New_Drug\" title=\"Investigational New Drug\">Investigational New Drug</a> (IND) Studies.<sup id=\"cite_ref-cder2006_3-0\" class=\"reference\"><a href=\"#cite_note-cder2006-3\">&#91;3&#93;</a></sup> Phase 0 trials are also known as human <a href=\"/wiki/Microdosing\" title=\"Microdosing\">microdosing</a> studies and are designed to speed up the development of promising drugs or <a href=\"/wiki/Contrast_medium\" class=\"mw-redirect\" title=\"Contrast medium\">imaging agents</a> by establishing very early on whether the drug or agent behaves in human subjects as was expected from preclinical studies. Distinctive features of Phase 0 trials include the administration of single subtherapeutic doses of the study drug to a small number of subjects (10 to 15) to gather preliminary data on the agent's  <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetics</a> (what the body does to the drugs).<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>\n</p><p>A Phase 0 study gives no data on safety or efficacy, being by definition a dose too low to cause any therapeutic effect. Drug development companies carry out Phase 0 studies to rank drug candidates in order to decide which has the best <a href=\"/wiki/Pharmacokinetic\" class=\"mw-redirect\" title=\"Pharmacokinetic\">pharmacokinetic</a> parameters in humans to take forward into further development. They enable go/no-go decisions to be based on relevant human models instead of relying on sometimes inconsistent animal data.\n</p>\n<h2><span class=\"mw-headline\" id=\"Phase_I\">Phase I</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=4\" title=\"Edit section: Phase I\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Phase I trials were formerly referred to as \u201cfirst-in-man studies\u201d but the field generally moved to the <a href=\"/wiki/Gender-neutral_language\" title=\"Gender-neutral language\">gender-neutral language</a> phrase \"first-in-humans\" in the 1990s;<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> these trials are the first stage of testing in human subjects.<sup id=\"cite_ref-ccs_6-0\" class=\"reference\"><a href=\"#cite_note-ccs-6\">&#91;6&#93;</a></sup> They are designed to test the safety, side effects, best dose, and formulation method for the drug.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</p><p>Normally, a small group of 2\u2013100 healthy volunteers will be recruited.<sup id=\"cite_ref-fda_2-1\" class=\"reference\"><a href=\"#cite_note-fda-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-ccs_6-1\" class=\"reference\"><a href=\"#cite_note-ccs-6\">&#91;6&#93;</a></sup> These trials are often conducted in a clinical trial clinic, where the subject can be observed by full-time staff. These clinical trial clinics are often run by <a href=\"/wiki/Contract_research_organization\" title=\"Contract research organization\">contract research organization</a> (CROs) who conduct these studies on behalf of <a href=\"/wiki/Pharmaceutical_companies\" class=\"mw-redirect\" title=\"Pharmaceutical companies\">pharmaceutical companies</a> or other research investigators. The subject who receives the drug is usually observed until several <a href=\"/wiki/Biological_half-life\" title=\"Biological half-life\">half-lives</a> of the drug have passed. This phase is designed to assess the safety (<a href=\"/wiki/Pharmacovigilance\" title=\"Pharmacovigilance\">pharmacovigilance</a>), tolerability, <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetics</a>, and <a href=\"/wiki/Pharmacodynamics\" title=\"Pharmacodynamics\">pharmacodynamics</a> of a drug. Phase I trials normally include <a href=\"/wiki/Dose-ranging\" class=\"mw-redirect\" title=\"Dose-ranging\">dose-ranging</a>, also called dose escalation studies, so that the best and safest dose can be found and to discover the point at which a compound is too poisonous to administer.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup> The tested range of doses will usually be a fraction<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers\" title=\"Wikipedia:Manual of Style/Dates and numbers\"><span title=\"This term requires quantification. (November 2011)\">quantify</span></a></i>&#93;</sup> of the dose that caused harm in <a href=\"/wiki/Animal_testing\" title=\"Animal testing\">animal testing</a>. Phase I trials most often include healthy volunteers. However, there are some circumstances when clinical patients are used, such as patients who have <a href=\"/wiki/Terminal_illness\" title=\"Terminal illness\">terminal</a> cancer or <a href=\"/wiki/HIV\" title=\"HIV\">HIV</a> and the treatment is likely to make healthy individuals ill. These studies are usually conducted in tightly controlled clinics called CPUs (Central Pharmacological Units), where participants receive 24-hour medical attention and oversight. In addition to the previously mentioned unhealthy individuals, \u201cpatients who have typically already tried and failed to improve on the existing standard therapies\"<sup id=\"cite_ref-DeMets_1-1\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup> may also participate in phase I trials.  Volunteers are paid a variable inconvenience fee for their time spent in the volunteer center.\n</p><p>Before beginning a phase I trial, the sponsor must submit an <a href=\"/wiki/Investigational_New_Drug\" title=\"Investigational New Drug\">Investigational New Drug</a> application to the FDA detailing the preliminary data on the drug gathered from cellular models and animal studies.\n</p><p>Phase I trials can be further divided:\n</p>\n<dl><dt>Single ascending dose (Phase Ia)</dt>\n<dd>In single ascending dose studies, small groups of subjects are given a single dose of the drug while they are observed and tested for a period of time to confirm safety.<sup id=\"cite_ref-ccs_6-2\" class=\"reference\"><a href=\"#cite_note-ccs-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-p1ct_9-0\" class=\"reference\"><a href=\"#cite_note-p1ct-9\">&#91;9&#93;</a></sup>  Typically, a small number of participants, usually three, are entered sequentially at a particular dose.<sup id=\"cite_ref-DeMets_1-2\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>  If they do not exhibit any <a href=\"/wiki/Adverse_event\" title=\"Adverse event\">adverse</a> side effects, and the pharmacokinetic data are roughly in line with predicted safe values, the dose is escalated, and a new group of subjects is then given a higher dose.  If unacceptable toxicity is observed in any of the three participants, an additional number of participants, usually three, are treated at the same dose.<sup id=\"cite_ref-DeMets_1-3\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>  This is continued until pre-calculated pharmacokinetic safety levels are reached, or intolerable side effects start showing up (at which point the drug is said to have reached the <a href=\"/wiki/Maximum_tolerated_dose\" class=\"mw-redirect\" title=\"Maximum tolerated dose\">maximum tolerated dose</a> (MTD)).  If an additional unacceptable toxicity is observed, then the dose escalation is terminated and that dose, or perhaps the previous dose, is declared to be the maximally tolerated dose.  This particular design assumes that the maximally tolerated dose occurs when approximately one-third of the participants experience unacceptable toxicity.  Variations of this design exist, but most are similar.<sup id=\"cite_ref-DeMets_1-4\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup></dd></dl>\n<dl><dt>Multiple ascending dose (Phase Ib)</dt>\n<dd>Multiple ascending dose studies investigate the pharmacokinetics and pharmacodynamics of multiple doses of the drug, looking at safety and tolerability. In these studies, a group of patients receives multiple low doses of the drug, while samples (of blood, and other fluids) are collected at various time points and analyzed to acquire information on how the drug is processed within the body. The dose is subsequently escalated for further groups, up to a predetermined level.<sup id=\"cite_ref-ccs_6-3\" class=\"reference\"><a href=\"#cite_note-ccs-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-p1ct_9-1\" class=\"reference\"><a href=\"#cite_note-p1ct-9\">&#91;9&#93;</a></sup></dd></dl>\n<dl><dt>Food effect</dt>\n<dd>A short trial designed to investigate any differences in absorption of the drug by the body, caused by eating before the drug is given. These studies are usually run as a <a href=\"/wiki/Crossover_study\" title=\"Crossover study\">crossover study</a>, with volunteers being given two identical doses of the drug while <a href=\"/wiki/Fasting\" title=\"Fasting\">fasted</a>, and after being fed.</dd></dl>\n<h2><span class=\"mw-headline\" id=\"Phase_II\">Phase II</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=5\" title=\"Edit section: Phase II\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Once a dose or range of doses is determined, the next goal is to evaluate whether the drug has any biological activity or effect.<sup id=\"cite_ref-DeMets_1-5\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>  Phase II trials are performed on larger groups (100\u2013300) and are designed to assess how well the drug works, as well as to continue Phase I safety assessments in a larger group of volunteers and patients.  Genetic testing is common, particularly when there is evidence of variation in metabolic rate.<sup id=\"cite_ref-DeMets_1-6\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>  When the development process for a new drug fails, this usually occurs during Phase II trials when the drug is discovered not to work as planned, or to have toxic effects.\n</p><p>Phase II studies are sometimes divided into Phase IIA and Phase IIB. There is no formal definition for these 2 sub-categories, but generally:\n</p>\n<ul><li>Phase IIA studies are usually pilot studies designed to demonstrate clinical efficacy or biological activity ('proof of concept' studies);</li>\n<li>Phase IIB studies look to find the optimum dose at which the drug shows biological activity with minimal side-effects (\u2018definite dose-finding\u2019 studies).</li></ul>\n<p>Some trials combine Phase I and Phase II, and test both efficacy and toxicity.\n</p>\n<dl><dt>Trial design</dt>\n<dd>Some Phase II trials are designed as <a href=\"/wiki/Case_series\" title=\"Case series\">case series</a>, demonstrating a drug's safety and activity in a selected group of patients. Other Phase II trials are designed as <a href=\"/wiki/Randomized_controlled_trial\" title=\"Randomized controlled trial\">randomized controlled trials</a>, where some patients receive the drug/device and others receive placebo/standard treatment. Randomized Phase II trials have far fewer patients than randomized Phase III trials.</dd></dl>\n<dl><dt>Example Cancer Design</dt>\n<dd>In the first stage, the investigator attempts to rule out drugs which have no or little biologic activity.  For example, the researcher may specify that a drug must have some minimal level of activity, say, in 20% of participants.  If the estimated activity level is less than 20%, the researcher chooses not to consider this drug further, at least not at that maximally tolerated dose.  If the estimated activity level exceeds 20%, the researcher will add more participants to get a better estimate of the response rate.  A typical study for ruling out a 20% or lower response rate enters 14 participants.  If no response is observed in the first 14 participants, the drug is considered not likely to have a 20% or higher activity level.  The number of additional participants added depends on the degree of precision desired, but ranges from 10 to 20.  Thus, a typical cancer phase II study might include fewer than 30 people to estimate the response rate.<sup id=\"cite_ref-DeMets_1-7\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup></dd></dl>\n<dl><dt>Efficacy vs Effectiveness</dt>\n<dd>When a study assesses efficacy, it is looking at whether the drug given in the specific manner described in the study is able to influence an outcome of interest (e.g. tumor size) in the chosen population (e.g. cancer patients with no other ongoing diseases). When a study is assessing effectiveness, it is determining whether a treatment will influence the disease. In an effectiveness study it is essential that patients are treated as they would be when the treatment is prescribed in actual practice. That would mean that there should be no aspects of the study designed to increase patient compliance above those that would occur in routine clinical practice. The outcomes in effectiveness studies are also more generally applicable than in most efficacy studies (for example does the patient feel better, come to the hospital less or live longer in effectiveness studies as opposed to better test scores or lower cell counts in efficacy studies). There is usually less rigid control of the type of patient to be included in effectiveness studies than in efficacy studies, as the researchers are interested in whether the drug will have a broad effect in the population of patients with the disease.</dd></dl>\n<p>Some researchers argue that phase II studies are generally smaller than they ought to be.<sup id=\"cite_ref-DeMets_1-8\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Success_rate\">Success rate</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=6\" title=\"Edit section: Success rate\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Phase II clinical programs historically have experienced the lowest success rate of the four development phases.  In 2010, the percentage of phase II trials that proceeded to phase III was 18%,<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup>  and only 30.7% of developmental candidates advanced from Phase II to Phase III in a large study of trials from 2006-2015.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Phase_III\">Phase III</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=7\" title=\"Edit section: Phase III\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>This phase is designed to assess the effectiveness of the new intervention and, thereby, its value in clinical practice.<sup id=\"cite_ref-DeMets_1-9\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>  Phase III studies are randomized controlled <a href=\"/wiki/Multicenter_trial\" title=\"Multicenter trial\">multicenter trials</a> on large patient groups (300\u20133,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how effective the drug is, in comparison with current 'gold standard' treatment. Because of their size and comparatively long duration, Phase III trials are the most expensive, time-consuming and difficult trials to design and run, especially in therapies for <a href=\"/wiki/Chronic_(medicine)\" class=\"mw-redirect\" title=\"Chronic (medicine)\">chronic</a> medical conditions. Phase III trials of chronic conditions or diseases often have a short follow-up period for evaluation, relative to the period of time the intervention might be used in practice.<sup id=\"cite_ref-DeMets_1-10\" class=\"reference\"><a href=\"#cite_note-DeMets-1\">&#91;1&#93;</a></sup>  This is sometimes called the \"pre-marketing phase\" because it actually measures consumer response to the drug.\n</p><p>It is common practice that certain Phase III trials will continue while the regulatory submission is pending at the appropriate regulatory agency. This allows patients to continue to receive possibly lifesaving drugs until the drug can be obtained by purchase. Other reasons for performing trials at this stage include attempts by the sponsor at \"label expansion\" (to show the drug works for additional types of patients/diseases beyond the original use for which the drug was approved for marketing), to obtain additional safety data, or to support marketing claims for the drug. Studies in this phase are by some companies categorized as \"Phase IIIB studies.\"<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n</p><p>While not required in all cases, it is typically expected that there be at least two successful Phase III trials, demonstrating a drug's safety and efficacy, in order to obtain approval from the appropriate regulatory agencies such as <a href=\"/wiki/U.S._Food_and_Drug_Administration\" class=\"mw-redirect\" title=\"U.S. Food and Drug Administration\">FDA</a> (USA), or the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">EMA</a> (European Union).\n</p><p>Once a drug has proved satisfactory after Phase III trials, the trial results are usually combined into a large document containing a comprehensive description of the methods and results of human and animal studies, manufacturing procedures, formulation details, and shelf life. This collection of information makes up the \"regulatory submission\" that is provided for review to the appropriate regulatory authorities<sup id=\"cite_ref-reg-auth_13-0\" class=\"reference\"><a href=\"#cite_note-reg-auth-13\">&#91;13&#93;</a></sup> in different countries. They will review the submission, and, it is hoped, give the sponsor approval to market the drug.\n</p><p>Most drugs undergoing Phase III clinical trials can be marketed under FDA norms with proper recommendations and guidelines through a <a href=\"/wiki/New_Drug_Application\" title=\"New Drug Application\">New Drug Application</a> (NDA) containing all manufacturing, pre-clinical, and clinical data. In case of any adverse effects being reported anywhere, the drugs need to be recalled immediately from the market.  While most pharmaceutical companies refrain from this practice, it is not abnormal to see many drugs undergoing Phase III clinical trials in the market.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Success_rate_2\">Success rate</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=8\" title=\"Edit section: Success rate\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>As of 2010, about 50% of drug candidates either fail during the Phase III trial or are rejected by the national regulatory agency.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup>\n</p><p><b>Phase II/III cost</b>\n</p><p>The amount of money spent on Phase II/III trials depends on numerous factors, with therapeutic area being studied and types of clinical procedures as key drivers; Phase II studies may cost as much as $20 million, and Phase III as much as $53 million.<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Phase_IV\">Phase IV</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=9\" title=\"Edit section: Phase IV\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>A Phase IV trial is also known as <a href=\"/wiki/Postmarketing_surveillance\" title=\"Postmarketing surveillance\">postmarketing surveillance</a> trial, or informally as a <a href=\"/wiki/Confirmatory_trial\" title=\"Confirmatory trial\">confirmatory trial</a>. Phase IV trials involve the safety surveillance (<a href=\"/wiki/Pharmacovigilance\" title=\"Pharmacovigilance\">pharmacovigilance</a>) and ongoing technical support of a drug after it receives permission to be sold (e.g. after approval under the <a href=\"/wiki/FDA_Accelerated_Approval_Program\" class=\"mw-redirect\" title=\"FDA Accelerated Approval Program\">FDA Accelerated Approval Program</a>).<sup id=\"cite_ref-acs_17-0\" class=\"reference\"><a href=\"#cite_note-acs-17\">&#91;17&#93;</a></sup> Phase IV studies may be required by regulatory authorities or may be undertaken by the sponsoring company for competitive (finding a new market for the drug) or other reasons (for example, the drug may not have been tested for interactions with other drugs, or on certain population groups such as pregnant women, who are unlikely to subject themselves to trials).<sup id=\"cite_ref-fda_2-2\" class=\"reference\"><a href=\"#cite_note-fda-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-ccs_6-4\" class=\"reference\"><a href=\"#cite_note-ccs-6\">&#91;6&#93;</a></sup> The safety surveillance is designed to detect any rare or long-term adverse effects over a much larger patient population and longer time period than was possible during the Phase I-III clinical trials.<sup id=\"cite_ref-ccs_6-5\" class=\"reference\"><a href=\"#cite_note-ccs-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-acs_17-1\" class=\"reference\"><a href=\"#cite_note-acs-17\">&#91;17&#93;</a></sup> Harmful effects discovered by Phase IV trials may result in a drug being no longer sold, or restricted to certain uses; recent examples involve <a href=\"/wiki/Cerivastatin\" title=\"Cerivastatin\">cerivastatin</a> (brand names Baycol and Lipobay), <a href=\"/wiki/Troglitazone\" title=\"Troglitazone\">troglitazone</a> (Rezulin) and <a href=\"/wiki/Rofecoxib\" title=\"Rofecoxib\">rofecoxib</a> (Vioxx). The minimum time period mandatory for Phase IV clinical trials is 2 years.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (November 2016)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Overall_cost\">Overall cost</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=10\" title=\"Edit section: Overall cost\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The entire process of developing a drug from preclinical research to marketing can take approximately 12 to 18 years and often costs well over $1 billion.<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Phases_of_clinical_research&amp;action=edit&amp;section=11\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-DeMets-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-DeMets_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-DeMets_1-10\"><sup><i><b>k</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">DeMets, D., Friedman, L., and Furberg, C. (2010). <i>Fundamentals of Clinical Trials</i> (4th ed.). Springer. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-1-4419-1585-6\" title=\"Special:BookSources/978-1-4419-1585-6\">978-1-4419-1585-6</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Fundamentals+of+Clinical+Trials&amp;rft.edition=4th&amp;rft.pub=Springer&amp;rft.date=2010&amp;rft.isbn=978-1-4419-1585-6&amp;rft.au=DeMets%2C+D.%2C+Friedman%2C+L.%2C+and+Furberg%2C+C.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Multiple names: authors list (<a href=\"/wiki/Category:CS1_maint:_Multiple_names:_authors_list\" title=\"Category:CS1 maint: Multiple names: authors list\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-fda-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-fda_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-fda_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-fda_2-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm\">\"Step 3. Clinical research\"</a>. US Food and Drug Administration. 14 October 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">1 February</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Step+3.+Clinical+research&amp;rft.pub=US+Food+and+Drug+Administration&amp;rft.date=2016-10-14&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FForPatients%2FApprovals%2FDrugs%2Fucm405622.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-cder2006-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-cder2006_3-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a href=\"/wiki/Center_for_Drug_Evaluation_and_Research\" title=\"Center for Drug Evaluation and Research\">CDER</a> (January 2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf\">\"Exploratory IND Studies\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Guidance for Industry, Investigators, and Reviewers. <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2010-06-15</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Exploratory+IND+Studies&amp;rft.series=Guidance+for+Industry%2C+Investigators%2C+and+Reviewers&amp;rft.pub=Food+and+Drug+Administration&amp;rft.date=2006-01&amp;rft.au=CDER&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fucm078933.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">The Lancet (2009). \"Phase 0 trials: a platform for drug development?\". <i>Lancet</i>. <b>374</b> (9685): 176. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2809%2961309-X\">10.1016/S0140-6736(09)61309-X</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19616703\">19616703</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Phase+0+trials%3A+a+platform+for+drug+development%3F&amp;rft.volume=374&amp;rft.issue=9685&amp;rft.pages=176&amp;rft.date=2009&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2809%2961309-X&amp;rft_id=info%3Apmid%2F19616703&amp;rft.au=The+Lancet&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Fisher, JA (1 March 2015). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4405793\">\"Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials\"</a>. <i>Science, technology &amp; human values</i>. <b>40</b> (2): 199\u2013226. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/0162243914554838\">10.1177/0162243914554838</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4405793\">4405793</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25914430\">25914430</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science%2C+technology+%26+human+values&amp;rft.atitle=Feeding+and+Bleeding%3A+The+Institutional+Banalization+of+Risk+to+Healthy+Volunteers+in+Phase+I+Pharmaceutical+Clinical+Trials.&amp;rft.volume=40&amp;rft.issue=2&amp;rft.pages=199-226&amp;rft.date=2015-03-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4405793&amp;rft_id=info%3Apmid%2F25914430&amp;rft_id=info%3Adoi%2F10.1177%2F0162243914554838&amp;rft.aulast=Fisher&amp;rft.aufirst=JA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4405793&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ccs-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ccs_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ccs_6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ccs_6-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ccs_6-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ccs_6-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-ccs_6-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/clinical-trials/phases-of-clinical-trials/?region=on\">\"Phases of clinical trials\"</a>. Canadian Cancer Society. 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">1 February</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Phases+of+clinical+trials&amp;rft.pub=Canadian+Cancer+Society&amp;rft.date=2017&amp;rft_id=http%3A%2F%2Fwww.cancer.ca%2Fen%2Fcancer-information%2Fdiagnosis-and-treatment%2Fclinical-trials%2Fphases-of-clinical-trials%2F%3Fregion%3Don&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/phase-i-clinical-trial\">\"NCI Dictionary\"</a>. National Cancer Institute.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NCI+Dictionary&amp;rft.pub=National+Cancer+Institute&amp;rft_id=https%3A%2F%2Fwww.cancer.gov%2Fpublications%2Fdictionaries%2Fcancer-terms%2Fdef%2Fphase-i-clinical-trial&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Adil E. Shamoo (2008). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.medscape.com/viewarticle/582554_2\">\"The Myth of Equipoise in Phase 1 Clinical Trials\"</a>. <i>Medscape J Med</i>. <b>10</b> (11): 254. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2605120\">2605120</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19099004\">19099004</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medscape+J+Med&amp;rft.atitle=The+Myth+of+Equipoise+in+Phase+1+Clinical+Trials&amp;rft.volume=10&amp;rft.issue=11&amp;rft.pages=254&amp;rft.date=2008&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2605120&amp;rft_id=info%3Apmid%2F19099004&amp;rft.au=Adil+E.+Shamoo&amp;rft_id=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F582554_2&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span style=\"font-size:0.95em; font-size:90%; color:#555\">(<a href=\"/wiki/Wikipedia:Verifiability#Access_to_sources\" title=\"Wikipedia:Verifiability\">registration required</a>)</span></span>\n</li>\n<li id=\"cite_note-p1ct-9\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-p1ct_9-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-p1ct_9-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Elizabeth Norfleet, Shayne Cox Gad, \"Phase I Clinical Trials\", in Shayne Cox Gad, <i>Clinical Trials Handbook</i>, <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-470-46635-3\" title=\"Special:BookSources/978-0-470-46635-3\">978-0-470-46635-3</a>, 2009, p. 247</span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://medcitynews.com/2011/06/new-drug-failure-rates-rising-in-phase-ii-and-iii-clinical-trials/\">\"New drugs failing Phase II and III clinical trials\"</a>. MedCity News.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=New+drugs+failing+Phase+II+and+III+clinical+trials&amp;rft.pub=MedCity+News&amp;rft_id=http%3A%2F%2Fmedcitynews.com%2F2011%2F06%2Fnew-drug-failure-rates-rising-in-phase-ii-and-iii-clinical-trials%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf\">\"Clinical Development Success Rates 2006-2015\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>bio.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-02-11</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=bio.org&amp;rft.atitle=Clinical+Development+Success+Rates+2006-2015&amp;rft_id=https%3A%2F%2Fwww.bio.org%2Fsites%2Fdefault%2Ffiles%2FClinical%2520Development%2520Success%2520Rates%25202006-2015%2520-%2520BIO%2C%2520Biomedtracker%2C%2520Amplion%25202016.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html\">\"Guidance for Institutional Review Boards and Clinical Investigators\"</a>. <a href=\"/wiki/Food_and_Drug_Administration_(United_States)\" class=\"mw-redirect\" title=\"Food and Drug Administration (United States)\">Food and Drug Administration</a>. 1999-03-16<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-03-27</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Guidance+for+Institutional+Review+Boards+and+Clinical+Investigators&amp;rft.pub=Food+and+Drug+Administration&amp;rft.date=1999-03-16&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Foc%2Fohrt%2Firbs%2Fdrugsbiologics.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-reg-auth-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-reg-auth_13-0\">^</a></b></span> <span class=\"reference-text\">The regulatory authority in the USA is the <a href=\"/wiki/Food_and_Drug_Administration_(United_States)\" class=\"mw-redirect\" title=\"Food and Drug Administration (United States)\">Food and Drug Administration</a>; in Canada, <a href=\"/wiki/Health_Canada\" title=\"Health Canada\">Health Canada</a>; in the <a href=\"/wiki/European_Union\" title=\"European Union\">European Union</a>, the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a>; and in Japan, the <a href=\"/wiki/Ministry_of_Health,_Labour_and_Welfare_(Japan)\" class=\"mw-redirect\" title=\"Ministry of Health, Labour and Welfare (Japan)\">Ministry of Health, Labour and Welfare</a></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Arcangelo, Virginia Poole; Andrew M. Peterson (2005). <i>Pharmacotherapeutics for Advanced Practice: A Practical Approach</i>. <a href=\"/wiki/Lippincott_Williams_%26_Wilkins\" title=\"Lippincott Williams &amp; Wilkins\">Lippincott Williams &amp; Wilkins</a>. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-7817-5784-3\" title=\"Special:BookSources/0-7817-5784-3\">0-7817-5784-3</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmacotherapeutics+for+Advanced+Practice%3A+A+Practical+Approach&amp;rft.pub=Lippincott+Williams+%26+Wilkins&amp;rft.date=2005&amp;rft.isbn=0-7817-5784-3&amp;rft.aulast=Arcangelo&amp;rft.aufirst=Virginia+Poole&amp;rft.au=Andrew+M.+Peterson&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Arrowsmith, John (1 February 2011). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/nrd/journal/v10/n2/full/nrd3375.html\">\"Trial watch: Phase III and submission failures: 2007\u20132010\"</a>. <i>Nat Rev Drug Discov</i>. <b>10</b> (2): 87\u201387. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nrd3375\">10.1038/nrd3375</a>  &#8211; via www.nature.com.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat+Rev+Drug+Discov&amp;rft.atitle=Trial+watch%3A+Phase+III+and+submission+failures%3A+2007%E2%80%932010&amp;rft.volume=10&amp;rft.issue=2&amp;rft.pages=87-87&amp;rft.date=2011-02-01&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd3375&amp;rft.aulast=Arrowsmith&amp;rft.aufirst=John&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fnrd%2Fjournal%2Fv10%2Fn2%2Ffull%2Fnrd3375.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Sertkaya, A; Wong, H. H.; Jessup, A; Beleche, T (2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://journals.sagepub.com/doi/10.1177/1740774515625964\">\"Key cost drivers of pharmaceutical clinical trials in the United States\"</a>. <i>Clinical Trials</i>. <b>13</b> (2): 117\u201326. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/1740774515625964\">10.1177/1740774515625964</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26908540\">26908540</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Trials&amp;rft.atitle=Key+cost+drivers+of+pharmaceutical+clinical+trials+in+the+United+States&amp;rft.volume=13&amp;rft.issue=2&amp;rft.pages=117-26&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1177%2F1740774515625964&amp;rft_id=info%3Apmid%2F26908540&amp;rft.aulast=Sertkaya&amp;rft.aufirst=A&amp;rft.au=Wong%2C+H.+H.&amp;rft.au=Jessup%2C+A&amp;rft.au=Beleche%2C+T&amp;rft_id=http%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F1740774515625964&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-acs-17\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-acs_17-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-acs_17-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html\">\"What Are the Phases of Clinical Trials?\"</a>. American Cancer Society. 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 July</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=What+Are+the+Phases+of+Clinical+Trials%3F&amp;rft.pub=American+Cancer+Society&amp;rft.date=2017&amp;rft_id=https%3A%2F%2Fwww.cancer.org%2Ftreatment%2Ftreatments-and-side-effects%2Fclinical-trials%2Fwhat-you-need-to-know%2Fphases-of-clinical-trials.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Holland, John (2013). \"Fixing a broken drug development process\". <i>Journal of Commercial Biotechnology</i>. <b>19</b>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.5912/jcb588\">10.5912/jcb588</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Commercial+Biotechnology&amp;rft.atitle=Fixing+a+broken+drug+development+process&amp;rft.volume=19&amp;rft.date=2013&amp;rft_id=info%3Adoi%2F10.5912%2Fjcb588&amp;rft.aulast=Holland&amp;rft.aufirst=John&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Adams, C. P.; Brantner, V. V. (2006). \"Estimating the Cost of New Drug Development: Is It Really $802 Million?\". <i>Health Affairs</i>. <b>25</b> (2): 420\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1377/hlthaff.25.2.420\">10.1377/hlthaff.25.2.420</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/16522582\">16522582</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Estimating+the+Cost+of+New+Drug+Development%3A+Is+It+Really+%24802+Million%3F&amp;rft.volume=25&amp;rft.issue=2&amp;rft.pages=420-8&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.25.2.420&amp;rft_id=info%3Apmid%2F16522582&amp;rft.aulast=Adams&amp;rft.aufirst=C.+P.&amp;rft.au=Brantner%2C+V.+V.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APhases+of+clinical+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Drug_design\" style=\"padding:3px\"><table class=\"nowraplinks collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Drug_design\" title=\"Template:Drug design\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Drug_design\" title=\"Template talk:Drug design\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Drug_design&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Drug_design\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Drug_design\" title=\"Drug design\">Drug design</a></div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Steps in design</th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Drug_discovery\" title=\"Drug discovery\">Drug discovery</a></li>\n<li><a href=\"/wiki/Hit_to_lead\" title=\"Hit to lead\">Hit to lead</a></li>\n<li><a href=\"/wiki/Drug_development\" title=\"Drug development\">Drug development</a>\n<ul><li><a href=\"/wiki/Pre-clinical_development\" title=\"Pre-clinical development\">Pre-clinical</a></li>\n<li><a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">Clinical</a>\n<ul><li><a class=\"mw-selflink selflink\">Phases</a></li></ul></li></ul></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Case studies of discovery <br /> and development of drug classes</th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Discovery_and_development_of_5%CE%B1-reductase_inhibitors\" title=\"Discovery and development of 5\u03b1-reductase inhibitors\">5\u03b1-Reductase inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_ACE_inhibitors\" title=\"Discovery and development of ACE inhibitors\">ACE inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_angiotensin_receptor_blockers\" title=\"Discovery and development of angiotensin receptor blockers\">Angiotensin receptor blockers</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_antiandrogens\" title=\"Discovery and development of antiandrogens\">Antiandrogens</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_beta-adrenergic_receptor_antagonists_(beta-blockers)\" class=\"mw-redirect\" title=\"Discovery and development of beta-adrenergic receptor antagonists (beta-blockers)\">Beta-blockers</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_beta2_agonists\" title=\"Discovery and development of beta2 agonists\">Beta<sub>2</sub> agonists</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_cephalosporins\" title=\"Discovery and development of cephalosporins\">Cephalosporins</a></li>\n<li><a href=\"/wiki/C-Met_inhibitors\" class=\"mw-redirect\" title=\"C-Met inhibitors\">c-Met inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_cyclooxygenase_2_inhibitors\" title=\"Discovery and development of cyclooxygenase 2 inhibitors\">Cyclooxygenase 2 inhibitors</a></li>\n<li><a href=\"/wiki/Development_of_dipeptidyl_peptidase-4_inhibitors\" class=\"mw-redirect\" title=\"Development of dipeptidyl peptidase-4 inhibitors\">Dipeptidyl peptidase-4 inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_direct_thrombin_inhibitors\" title=\"Discovery and development of direct thrombin inhibitors\">Direct thrombin inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_direct_Xa_inhibitors\" title=\"Discovery and development of direct Xa inhibitors\">Direct Xa inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_dual_serotonin_and_norepinephrine_reuptake_inhibitors\" class=\"mw-redirect\" title=\"Discovery and development of dual serotonin and norepinephrine reuptake inhibitors\">Dual serotonin and norepinephrine reuptake inhibitors</a></li>\n<li><a href=\"/wiki/Development_and_discovery_of_SSRI_drugs\" title=\"Development and discovery of SSRI drugs\">Selective serotonin reuptake inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_gliflozins\" title=\"Discovery and development of gliflozins\">Gliflozins</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_HIV-protease_inhibitors\" title=\"Discovery and development of HIV-protease inhibitors\">HIV-protease inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_integrase_inhibitors\" title=\"Discovery and development of integrase inhibitors\">Integrase inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_gastrointestinal_lipase_inhibitors\" title=\"Discovery and development of gastrointestinal lipase inhibitors\">Lipase inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_memantine_and_related_compounds\" class=\"mw-redirect\" title=\"Discovery and development of memantine and related compounds\">Memantine and related drugs</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_mTOR_inhibitors\" class=\"mw-redirect\" title=\"Discovery and development of mTOR inhibitors\">mTOR inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_Neuraminidase_Inhibitors\" class=\"mw-redirect\" title=\"Discovery and development of Neuraminidase Inhibitors\">Neuraminidase inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_non-nucleoside_reverse-transcriptase_inhibitors\" title=\"Discovery and development of non-nucleoside reverse-transcriptase inhibitors\">Non-nucleoside reverse-transcriptase inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_NS5A_inhibitors\" title=\"Discovery and development of NS5A inhibitors\">NS5A inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_nucleoside_and_nucleotide_reverse-transcriptase_inhibitors\" title=\"Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors\">Nucleoside and nucleotide reverse-transcriptase inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_phosphodiesterase_5_inhibitors\" title=\"Discovery and development of phosphodiesterase 5 inhibitors\">PDE5 inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_proton_pump_inhibitors\" title=\"Discovery and development of proton pump inhibitors\">Proton pump inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_statins\" title=\"Discovery and development of statins\">Statins</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_thalidomide_and_its_analogs\" class=\"mw-redirect\" title=\"Discovery and development of thalidomide and its analogs\">Thalidomide and its analogs</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_triptans\" title=\"Discovery and development of triptans\">Triptans</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_TRPV1_antagonists\" title=\"Discovery and development of TRPV1 antagonists\">TRPV1 antagonists</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_tubulin_inhibitors\" title=\"Discovery and development of tubulin inhibitors\">Tubulin inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_Bcr-Abl_tyrosine_kinase_inhibitors\" class=\"mw-redirect\" title=\"Discovery and development of Bcr-Abl tyrosine kinase inhibitors\">Bcr-Abl tyrosine-kinase inhibitors</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_Cannabinoid_Receptor_1_Antagonists\" class=\"mw-redirect\" title=\"Discovery and development of Cannabinoid Receptor 1 Antagonists\">Cannabinoid receptor antagonists</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_CCR5_receptor_antagonists\" class=\"mw-redirect\" title=\"Discovery and development of CCR5 receptor antagonists\">CCR5 receptor antagonists</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_neurokinin_1_receptor_antagonists\" class=\"mw-redirect\" title=\"Discovery and development of neurokinin 1 receptor antagonists\">Neurokinin 1 receptor antagonists</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_serotonin_receptor_antagonists\" class=\"mw-redirect\" title=\"Discovery and development of serotonin receptor antagonists\">5-HT<sub>3</sub> antagonists</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_melatonin_receptor_agonists\" class=\"mw-redirect\" title=\"Discovery and development of melatonin receptor agonists\">Melatonin receptor agonists</a></li>\n<li><a href=\"/wiki/Discovery_and_development_of_renin_inhibitors\" class=\"mw-redirect\" title=\"Discovery and development of renin inhibitors\">Renin inhibitors</a></li></ul>\n</div></td></tr></tbody></table></div>\n\n<!-- \nNewPP limit report\nParsed by mw1315\nCached time: 20180831092943\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.308 seconds\nReal time usage: 0.384 seconds\nPreprocessor visited node count: 1430/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 50588/2097152 bytes\nTemplate argument size: 1634/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 2/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 24994/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.129/10.000 seconds\nLua memory usage: 4.34 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  324.316      1 -total\n 54.97%  178.282      1 Template:Reflist\n 18.62%   60.396      2 Template:Fix\n 17.65%   57.249      1 Template:Quantify\n 13.77%   44.667      2 Template:Cite_book\n 11.69%   37.920      3 Template:Category_handler\n 10.46%   33.924      7 Template:Cite_journal\n 10.32%   33.483      8 Template:Cite_web\n  8.87%   28.772      1 Template:Main\n  8.80%   28.540      1 Template:ISBN\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:34382035-0!canonical and timestamp 20180831092946 and revision id 857380715\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D9%85%D8%B1%D8%A7%D8%AD%D9%84_%D8%A7%D9%84%D8%AA%D8%AC%D8%A7%D8%B1%D8%A8_%D8%A7%D9%84%D8%B3%D8%B1%D9%8A%D8%B1%D9%8A%D8%A9","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u0645\u0631\u0627\u062d\u0644 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629"},{"lang":"fa","url":"https://fa.wikipedia.org/wiki/%D9%85%D8%B1%D8%A7%D8%AD%D9%84_%DA%A9%D8%A7%D8%B1%D8%A2%D8%B2%D9%85%D8%A7%DB%8C%DB%8C_%D8%A8%D8%A7%D9%84%DB%8C%D9%86%DB%8C","langname":"Persian","autonym":"\u0641\u0627\u0631\u0633\u06cc","*":"\u0645\u0631\u0627\u062d\u0644 \u06a9\u0627\u0631\u0622\u0632\u0645\u0627\u06cc\u06cc \u0628\u0627\u0644\u06cc\u0646\u06cc"}],"categories":[{"sortkey":"","hidden":"","*":"CS1_maint:_Multiple_names:_authors_list"},{"sortkey":"","hidden":"","*":"Pages_with_login_required_references_or_sources"},{"sortkey":"","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"","hidden":"","*":"Articles_with_unsourced_statements_from_November_2011"},{"sortkey":"","hidden":"","*":"Articles_with_unsourced_statements_from_November_2016"},{"sortkey":"","*":"Clinical_research"},{"sortkey":"","*":"Design_of_experiments"},{"sortkey":"","*":"Life_sciences_industry"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2011"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2016"},{"ns":14,"exists":"","*":"Category:CS1 maint: Multiple names: authors list"},{"ns":10,"exists":"","*":"Template:Drug design"},{"ns":0,"exists":"","*":"Adverse event"},{"ns":0,"exists":"","*":"Animal testing"},{"ns":0,"exists":"","*":"Biological half-life"},{"ns":0,"exists":"","*":"C-Met inhibitors"},{"ns":0,"exists":"","*":"Case series"},{"ns":0,"exists":"","*":"Center for Drug Evaluation and Research"},{"ns":0,"exists":"","*":"Cerivastatin"},{"ns":0,"exists":"","*":"Chronic (medicine)"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Confirmatory trial"},{"ns":0,"exists":"","*":"Contract research organization"},{"ns":0,"exists":"","*":"Contrast medium"},{"ns":0,"exists":"","*":"Crossover study"},{"ns":0,"exists":"","*":"Development and discovery of SSRI drugs"},{"ns":0,"exists":"","*":"Development of dipeptidyl peptidase-4 inhibitors"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Discovery and development of 5\u03b1-reductase inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of ACE inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of Bcr-Abl tyrosine kinase inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of CCR5 receptor antagonists"},{"ns":0,"exists":"","*":"Discovery and development of Cannabinoid Receptor 1 Antagonists"},{"ns":0,"exists":"","*":"Discovery and development of HIV-protease inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of NS5A inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of Neuraminidase Inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of TRPV1 antagonists"},{"ns":0,"exists":"","*":"Discovery and development of angiotensin receptor blockers"},{"ns":0,"exists":"","*":"Discovery and development of antiandrogens"},{"ns":0,"exists":"","*":"Discovery and development of beta-adrenergic receptor antagonists (beta-blockers)"},{"ns":0,"exists":"","*":"Discovery and development of beta2 agonists"},{"ns":0,"exists":"","*":"Discovery and development of cephalosporins"},{"ns":0,"exists":"","*":"Discovery and development of cyclooxygenase 2 inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of direct Xa inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of direct thrombin inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of dual serotonin and norepinephrine reuptake inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of gastrointestinal lipase inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of gliflozins"},{"ns":0,"exists":"","*":"Discovery and development of integrase inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of mTOR inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of melatonin receptor agonists"},{"ns":0,"exists":"","*":"Discovery and development of memantine and related compounds"},{"ns":0,"exists":"","*":"Discovery and development of neurokinin 1 receptor antagonists"},{"ns":0,"exists":"","*":"Discovery and development of non-nucleoside reverse-transcriptase inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of phosphodiesterase 5 inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of proton pump inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of renin inhibitors"},{"ns":0,"exists":"","*":"Discovery and development of serotonin receptor antagonists"},{"ns":0,"exists":"","*":"Discovery and development of statins"},{"ns":0,"exists":"","*":"Discovery and development of thalidomide and its analogs"},{"ns":0,"exists":"","*":"Discovery and development of triptans"},{"ns":0,"exists":"","*":"Discovery and development of tubulin inhibitors"},{"ns":0,"exists":"","*":"Dose-ranging"},{"ns":0,"exists":"","*":"Drug design"},{"ns":0,"exists":"","*":"Drug development"},{"ns":0,"exists":"","*":"Drug discovery"},{"ns":0,"exists":"","*":"Efficacy"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"European Union"},{"ns":0,"exists":"","*":"FDA Accelerated Approval Program"},{"ns":0,"exists":"","*":"Fasting"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Food and Drug Administration (United States)"},{"ns":0,"exists":"","*":"Gender-neutral language"},{"ns":0,"exists":"","*":"HIV"},{"ns":0,"exists":"","*":"Health Canada"},{"ns":0,"exists":"","*":"Health intervention"},{"ns":0,"exists":"","*":"Hit to lead"},{"ns":0,"exists":"","*":"Human subject research"},{"ns":0,"exists":"","*":"In vitro"},{"ns":0,"exists":"","*":"In vivo"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"Investigational New Drug"},{"ns":0,"exists":"","*":"Investigational new drug"},{"ns":0,"exists":"","*":"Lippincott Williams & Wilkins"},{"ns":0,"exists":"","*":"Maximum tolerated dose"},{"ns":0,"exists":"","*":"Medical treatment"},{"ns":0,"exists":"","*":"Microdosing"},{"ns":0,"exists":"","*":"Ministry of Health, Labour and Welfare (Japan)"},{"ns":0,"exists":"","*":"Multicenter trial"},{"ns":0,"exists":"","*":"New Drug Application"},{"ns":0,"exists":"","*":"Pharmaceutical companies"},{"ns":0,"exists":"","*":"Pharmacodynamics"},{"ns":0,"exists":"","*":"Pharmacokinetic"},{"ns":0,"exists":"","*":"Pharmacokinetics"},{"ns":0,"exists":"","*":"Pharmacovigilance"},{"ns":0,"exists":"","*":"Postmarketing surveillance"},{"ns":0,"exists":"","*":"Pre-clinical development"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Randomized controlled trial"},{"ns":0,"exists":"","*":"Rofecoxib"},{"ns":0,"exists":"","*":"Terminal illness"},{"ns":0,"exists":"","*":"Toxicity"},{"ns":0,"exists":"","*":"Troglitazone"},{"ns":0,"exists":"","*":"U.S. Food and Drug Administration"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"},{"ns":4,"exists":"","*":"Wikipedia:Manual of Style/Dates and numbers"},{"ns":4,"exists":"","*":"Wikipedia:Verifiability"},{"ns":11,"exists":"","*":"Template talk:Drug design"}],"templates":[{"ns":10,"exists":"","*":"Template:Main"},{"ns":10,"exists":"","*":"Template:Quantify"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Registration required"},{"ns":10,"exists":"","*":"Template:Link note"},{"ns":10,"exists":"","*":"Template:ISBN"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Error-small"},{"ns":10,"exists":"","*":"Template:Tl"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Drug design"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":828,"exists":"","*":"Module:Main"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check isxn"},{"ns":828,"exists":"","*":"Module:Error"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Navbox"},{"ns":828,"exists":"","*":"Module:Navbar"}],"images":["Lock-green.svg"],"externallinks":["http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm","http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf","//doi.org/10.1016/S0140-6736(09)61309-X","//www.ncbi.nlm.nih.gov/pubmed/19616703","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4405793","//doi.org/10.1177/0162243914554838","//www.ncbi.nlm.nih.gov/pubmed/25914430","http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/clinical-trials/phases-of-clinical-trials/?region=on","https://www.cancer.gov/publications/dictionaries/cancer-terms/def/phase-i-clinical-trial","http://www.medscape.com/viewarticle/582554_2","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2605120","//www.ncbi.nlm.nih.gov/pubmed/19099004","http://medcitynews.com/2011/06/new-drug-failure-rates-rising-in-phase-ii-and-iii-clinical-trials/","https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf","http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html","http://www.nature.com/nrd/journal/v10/n2/full/nrd3375.html","//doi.org/10.1038/nrd3375","http://journals.sagepub.com/doi/10.1177/1740774515625964","//doi.org/10.1177/1740774515625964","//www.ncbi.nlm.nih.gov/pubmed/26908540","https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html","//doi.org/10.5912/jcb588","//doi.org/10.1377/hlthaff.25.2.420","//www.ncbi.nlm.nih.gov/pubmed/16522582"],"sections":[{"toclevel":1,"level":"2","line":"Summary","number":"1","index":"1","fromtitle":"Phases_of_clinical_research","byteoffset":613,"anchor":"Summary"},{"toclevel":1,"level":"2","line":"Pre-clinical studies","number":"2","index":"2","fromtitle":"Phases_of_clinical_research","byteoffset":3258,"anchor":"Pre-clinical_studies"},{"toclevel":1,"level":"2","line":"Phase 0","number":"3","index":"3","fromtitle":"Phases_of_clinical_research","byteoffset":3803,"anchor":"Phase_0"},{"toclevel":1,"level":"2","line":"Phase I","number":"4","index":"4","fromtitle":"Phases_of_clinical_research","byteoffset":5675,"anchor":"Phase_I"},{"toclevel":1,"level":"2","line":"Phase II","number":"5","index":"5","fromtitle":"Phases_of_clinical_research","byteoffset":11748,"anchor":"Phase_II"},{"toclevel":2,"level":"3","line":"Success rate","number":"5.1","index":"6","fromtitle":"Phases_of_clinical_research","byteoffset":15673,"anchor":"Success_rate"},{"toclevel":1,"level":"2","line":"Phase III","number":"6","index":"7","fromtitle":"Phases_of_clinical_research","byteoffset":16531,"anchor":"Phase_III"},{"toclevel":2,"level":"3","line":"Success rate","number":"6.1","index":"8","fromtitle":"Phases_of_clinical_research","byteoffset":20436,"anchor":"Success_rate_2"},{"toclevel":1,"level":"2","line":"Phase IV","number":"7","index":"9","fromtitle":"Phases_of_clinical_research","byteoffset":21544,"anchor":"Phase_IV"},{"toclevel":1,"level":"2","line":"Overall cost","number":"8","index":"10","fromtitle":"Phases_of_clinical_research","byteoffset":23167,"anchor":"Overall_cost"},{"toclevel":1,"level":"2","line":"References","number":"9","index":"11","fromtitle":"Phases_of_clinical_research","byteoffset":23864,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Phases of clinical research","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q7180990"}]}}